Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors

Third Cell Therapy For Lymphoma Approved In The US

Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah. 

FDA - Food and Drug Administration approved text on document above stethoscope
Breyanzi was approved after an FDA delay related to manufacturing inspections • Source: Shutterstock

The US Food and Drug Administration approval of Bristol Myers Squibb Company’s chimeric antigen receptor T-cell (CAR-T) therapy Breyanzi (lisocabtagene maraleucel; liso-cel) has been a long time coming, but that has given the company time to prepare for launch against two established competitors.

More from New Products

More from Scrip

AstraZeneca Oral PCSK9 Prospects Pumped After Phase IIb Win

 
• By 

The UK giant is forecasting peak sales of $5bn plus

Novo Scores Cardio Wins But Lilly Still Tipped To Take GLP-1 Crown

 

Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.

Pipeline Watch: Seventeen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.